distribution occurs rapidly in healthy subjects with a volume of distribution (Vd) of 0.4-1.0 L/kg. Critically ill patients present altered Vd and may reach two or three times the typical value. Its protein binding ranges from 10% to 50% and depends on the total serum concentration of proteins. The drug is not metabolized and its excretion is 80%-90% renal, with elimination half-life highly dependent on renal function. [4] [5] [6] In subjects with normal creatinine clearance, vancomycin has a distribution phase of 30 minutes to 1 hour and a half-life elimination of 6-12 hours. 4, 5, 7 Vancomycin penetrates most tissues although its concentration is variable and often depends on the degree of inflammation present.
Its penetration into the lung and central nervous system is poor, with a higher risk of subtherapeutic tissue concentration at lower doses. 5 Skin penetration is significantly lower in patients with diabetes when compared to patients without diabetes. 8 Its antibacterial action is time and concentration dependent. 4, 6 Based on the pharmacodynamics of vancomycin, an area under the curve (ratio) is recommended by the minimum inhibitory concentration (AUC/MIC) of 400 or greater for S. aureus with MIC ≤ 2 mg/L.
In a prospective study, Moise-Broder et al 9 identified in patients with pulmonary sepsis that time above MIC was 100% in all patients, but clinical success was about six times higher in those with AUC/ MIC above 400. This finding was obtained again in later studies, and AUC/MIC is now considered the best predictor of clinical outcomes. 4 A multicenter prospective cohort study conducted by Song et al 10 analyzed the association between 24-hour AUC and MIC with clinical outcomes in 117 patients with sepsis and infections caused by MRSA. Treatment failure, defined as 30-day mortality, persistent bacteraemia for more than 7 days, or recurrent infection in less than 30 days of treatment end was observed in 32.5% and was associated with low AUC/MIC ratio (OR 3.50 for microdilution method, . [12] [13] [14] Another emerging population of S. aureus is heteroresistant vancomycin-intermediate S. aureus (hVISA), considered to be the precursor of the VISA population. Although uncommon, this subpopulation seems to predict vancomycin treatment failure. 7, 14 Some clinical situations may require the combined use of vancomycin for the treatment of complicated infections, for example, vancomycin combined with rifampicin to treat prosthetic infections;
with gentamicin is MRSA bacteraemia; and with clindamycin to reduce toxin produced by S. aureus.
7
The two most common ways to determine the MIC of Staphylococcus sp. are by microdilution (results by dilution performed twice) or Etest (continuous gradient describing fractional dilutions). 6 Determining the AUC and subsequently the AUC/MIC ratio is impossible under normal circumstances due to the large number of serum samples that should be collected after a single dose.
Then, the standard recommendation is the use of serum trough level in a stable condition as a marker. 6 A meta-analysis conducted by van Hal et al 14 The use of attack dose has been proposed as a strategy to avoid subtherapeutic levels in the early stages of the treatment, soon achieving an AUC/MIC over 400, and without evidence of impact on nephrotoxicity. 13, 19, 20 A retrospective study conducted by Rosini et al 21 evaluated
2131 patients at three academic centres and compared the vancomycin dose of >20 to ≤20 mg/kg, and found a lower incidence of nephrotoxicity in the higher dose group (5.8% vs 11.1%, P < 0.001).
After patients, of whom 207 were obese, with similar groups, except for a higher female prevalence (P = 0.042), diabetes mellitus (P = 0.018) and hypertension (P = 0.0009) in the obese group. Obesity was not associated with an increased risk of nephrotoxicity (RR 0.98, CI 0.93-1.04, P = 0.59), unlike the APACHE II >21 severity score, which was correlated with nephrotoxicity (P = 0.039).
The most frequent recommendations for obese patients are an initial dose based on the current weight, not exceeding 2000 mg and adjustments of subsequent doses based on the therapeutic serum level. 6, 26, 27 Some specific populations require individual assessment, such as those with large burns. 28 In this population, a shorter administration interval and larger doses may be required; however, nomograms or therapeutic drug monitoring are recommended for adjustments. showed, in relation to the intermittent dose group, lower levels of urea (P = 0.041), creatinine (P = 0.009), leukocytes (P = 0.001), pCO2
| Intermittent vs continuous administration
(P = 0.025) and body temperature (P = 0.0001), as well as higher pO2
and saturation (P = 0.038). In addition, continuous infusion resulted in lower sub therapeutic level rates (30% vs 55%), higher optimal level rates (40% vs 10%) and similar toxic rates (30% vs 35%), as well as shorter treatment duration (P = 0.0001).
A study conducted by Cataldo et al 30 Despite its wide use in clinical practice, there are unresolved concerns about its effectiveness and safety. Regarding efficacy, mainly in critically ill patients, its pharmacokinetics is altered, due to drug distribution, metabolism and elimination, 1,32-34 which could lead to subtherapeutic serum concentration and develop bacterial resistance, with possible increased mortality. 35 In terms of safety, its main side effect-nephrotoxicity-has been widely discussed, with risk of AKI and complications in the short and long term. 
| Serum monitoring
Considering the great heterogeneity of patients, different degrees of organic dysfunction and pathophysiological changes in critically ill patients, therapeutic drug monitoring should be considered to achieve pharmacokinetic goals in ICUs; however, no study considers the costs of implementing such monitoring in hospital routines. 37 A randomized clinical study and five cohort studies were included in a meta-analysis conducted by Ye et al, 38 which showed therapeutic drug monitoring associated with higher clinical efficacy rates (OR 2.62, P = 0.005) and lower nephrotoxicity rates (OR 0.25, The frequency of monitoring, after reaching the therapeutic target, may be on a weekly basis for haemodynamically stable patients. In unstable patients, more frequent evaluations (in some situations on a daily basis) should be performed, but there is no exact frequency, and monitoring should be based on clinical judgment. 27, 37 A systematic review and a meta-analysis conducted by Steinmetz A meta-analysis of 14 cohorts conducted by Prybylski 45 showed that trough serum levels greater than 15 mg/L were not associated with reduced treatment failure, persistent bacteraemia or mortality.
On 
6,46
Vancomycin has almost exclusive renal elimination; however, the mechanism through which nephrotoxicity occurs is still not well understood. Studies in experimental animals suggest that oxidative stress induced by the drug in proximal renal tubule cells may lead to tubular ischaemia and acute tubulointerstitial damage. 47, 48 Both vancomycin build-up in kidney cells and alteration of mitochondrial function in proximal tubule cells have been proposed as the main factors of nephrotoxicity. [48] [49] [50] [51] Vancomycin crosses the basolateral membrane of the proximal tubular epithelium via organic acid transport system and via transport mediated by receptor megalin on the apical surface. Then, its injury to the tubule is mediated by oxidative stress, activation of inflammatory pathways and complement. 45, 52 Superoxides produced by vancomycin cause depolarization of the mitochondrial membrane potential, with release of cytochrome C and subsequent activation of caspases 3 and 9, related to cellular apoptosis. 45 Another potential mechanism of injury is tubular obstruction with cylinders containing vancomycin precipitates. 52 The incidence of nephrotoxicity caused by vancomycin varies greatly among various studies, with rates as low as zero in the absence of other concomitant nephrotoxins, up to 40% 8, 45, 51, 53 in combination with other potentially nephrotoxic drugs, with a higher prevalence frequently described from 5% to 7%, 45 involving different factors that may speed up or enhance the occurrence of nephrotoxicity, which may be related to the patient and/or the drug. 51 Among the patient-related factors, 48 Especially in septic patients admitted to the ICU, the presence of other factors concomitantly with the use of vancomycin makes it difficult to assess nephrotoxicity as the aetiology of AKI, since they act as confounding factors and make these patients more susceptible to kidney damage due to the severity of the underlying disease, and not due to the treatment. Then, some authors question whether high serum levels of vancomycin are the cause (due to higher serum concentration) or a consequence of AKI (drug build-up due to impaired kidney function as a consequence of other factors). 21 Data suggesting a causal relationship between doses and therapeutic targets of vancomycin and nephrotoxicity are conflicting and marked by confounding factors. 8 Although there is minimal evidence supporting efficacy in maintaining therapeutic levels be- of the cases, and in the group with Cr >1.4 mg/dL and vancomycin >20 mcg/mL, the odds ratio adjusted for the development of AKI was 3.17 (CI 1.05-9.56; P = 0.041).
Another study conducted by Iwamoto et al 42 also found that patients who were not monitored for therapeutic levels of vancomycin had a significant decrease in creatinine clearance values and, therefore, presented a higher risk of nephrotoxicity when compared to those who were monitored (OR = 0.25; P < 0.05).
In a recent publication, 56 High doses of vancomycin, associated with systemic inflammation and ischaemic insults in the septic patient, increase the risk of nephrotoxicity, which occurs 4 to 8 days after starting the use. 51 Nephrotoxicity is associated with longer hospitalization, higher expenses and mortality. 61 Kidney function recovery occurs in 44%-75% of the patients with nephrotoxicity after 1 week of drug discontinuation. 62 Table 1 summarizes the main recommendations for the prevention of nephrotoxicity found in the literature.
Defining vancomycin-associated nephrotoxicity can be a challenge. The most frequent definition is an increase of 0.5 mg/dL in serum creatinine or 50% increase above baseline in two consecutive measurements after several days of vancomycin and no other apparent causes. 8 Worsening of kidney function may be defined according to the most current criteria for acute kidney injury (AKI)
by the Kidney Disease Improving Global Outcomes (KDIGO) 35 as an increase greater than 0.3 mg/dL in baseline creatinine in 48 hours; increase of 1.5 times the baseline creatinine within 7 days; and/or reduction of urinary output to <0.5 mL/kg/h in 6 hours. However, serum creatinine may remain unchanged despite significant tubular injury, increasing only after 48-72 hours. Biomarkers that identify proximal tubular dysfunction, such as NGAL, KIM-1 and IL-18, can be used for early diagnosis of kidney injury and to establish prognosis. 45 The two most common ways of kidney function impairment by vancomycin are acute tubular necrosis (ATN) and acute interstitial nephritis (ASN). 45, 54 NIA is an immune-mediated reaction that presents symptoms and signs of hypersensitivity: temperature increase, maculopapular rash, eosinophilia, urinary sediments. 62, 63 The most common adverse events related to the administration of vancomycin and not related to serum concentration are linked with red man syndrome, associated with histamine release, developing paresthaesia and redness of the face, neck and thorax, when the administration of large doses occurs very fast (more than 500 mg in less than 30 minutes 8 ); suggested infusion period: 1 to 2 hours.
Other forms of toxicity include hypersensitivity reactions, such as In peritoneal dialysis, since 1956, after a study conducted by
Geraci et al, 78 vancomycin diffuses with the dialysate, reaching the concentration of 51% (23%-75%) of simultaneous serum level, with collections performed 1-2 hours after intravenous administration of 500 mg vancomycin. However, the literature has no current studies addressing this topic in details.
In septic patients with AKI, the prevention of new kidney issues, such as nephrotoxicity, is essential. Then, antimicrobial dose should be corrected, but there are no validated guidelines so far to help adjust antimicrobial doses in patients with AKI. In patients with SARS, except for continuous venovenous therapies with more antimicrobial dose studies, studies are scarce for other dialysis types, with recommendations from studies performed in non-critically ill patients and stable kidney function or with chronic kidney disease in the final stage receiving chronic renal replacement therapy. [76] [77] [78] [79] According to a narrative review conducted by Freitas et al, 71 the dose of 15 mg/kg should be administered after the dialysis for conventional HD therapies in daily regimen (or according to serum level), 500 mg every 24-48 hours in continuous venovenous therapies, 7.5 mg/kg every 2-3 days for continuous ambulatory peritoneal dialysis (CAPD). There is no specific information about doses for patients receiving extended HD therapy or high volume PD. However, the administration of 15 mg/kg in the last hour resulted in much lower pre-dialysis concentration.
| CON CLUS ION
Vancomycin is still one of the most widely used antimicrobials in hospital environments and in critically-ill populations, but studies involving the safety and efficacy of vancomycin in septic patients are still inconclusive, especially in patients with acute kidney injury and/ or concomitant dialysis therapies. Then, further studies are required to fill such knowledge gaps.
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